Quick Answer
Sunshine Biopharma Inc. reported Diluted EPS of $7.32 per share (loss) for fiscal year 2024.
Sunshine Biopharma Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$7.32 | +97.9% |
| 2023 | -$351.36 | -19863.6% |
| 2022 | -$1.76 | +63.0% |
| 2021 | -$4.76 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | -$0.44 | +78.0% | +78.0% |
| March 31, 2024 | -$2.00 | +74.1% | +74.1% |
| March 31, 2023 | -$7.73 | -3260.9% | -3260.9% |
| March 31, 2022 | -$0.23 | — | — |
- Sunshine Biopharma Inc. showed an increase of +97.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2024 period, Sunshine Biopharma Inc.’s diluted eps has declined by 53.8% (from $4.76 per share (loss) to $7.32 per share (loss)).
- The most recent figure is from Sunshine Biopharma Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 1, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: